Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (345)	12/12/1999 4:46:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

RWR, In 96 when I become SI member and started NXTR tread I make clear how I value any bt/pharma: 1. How they develop new drug, 2. How they manufacture (or secure from contract) drug, 3. How they market and sell drug Small bt can chose only first step and virtually integrate 2. and 3. part. However, by this they are missing big chunk of the profit. REGN approach is to integrate all three part in business model. So, ability to execute second part is significant step forward and did add value. Will WS or street recognize this or not, bit's me? This value may not be recognized today or tomorrow, but when BDNF reach NDA application status investors will look back. So, as long as my model work and I am satisfied with it I can be relaxed and continue to follow drug development progress. Focus on REGN drug pipeline should be main objective here. I agree. What is your opinion on BDNF, NT3, Axokine, cytokine traps, MAP kinases, angiogenesis, ....? Looking forward for few beers. Miljenko